CN1747730B - 肝细胞生长因子(分散因子)活性的吡唑衍生物调节剂 - Google Patents
肝细胞生长因子(分散因子)活性的吡唑衍生物调节剂 Download PDFInfo
- Publication number
- CN1747730B CN1747730B CN2003801095507A CN200380109550A CN1747730B CN 1747730 B CN1747730 B CN 1747730B CN 2003801095507 A CN2003801095507 A CN 2003801095507A CN 200380109550 A CN200380109550 A CN 200380109550A CN 1747730 B CN1747730 B CN 1747730B
- Authority
- CN
- China
- Prior art keywords
- compounds
- aryl
- alkyl
- disease
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CN(*)N=*C(C*)CC#C* Chemical compound CN(*)N=*C(C*)CC#C* 0.000 description 17
- QTEKDDDIGTUWGK-UHFFFAOYSA-N CC1=CN[IH]2=C=C12 Chemical compound CC1=CN[IH]2=C=C12 QTEKDDDIGTUWGK-UHFFFAOYSA-N 0.000 description 1
- KJRRQXYWFQKJIP-UHFFFAOYSA-N Cc1c[o]cc1 Chemical compound Cc1c[o]cc1 KJRRQXYWFQKJIP-UHFFFAOYSA-N 0.000 description 1
- ATYFLPYBMPJORO-RMKNXTFCSA-N O=C(C1CC1)[n]1nc(/C=C/c2ccccc2)cc1 Chemical compound O=C(C1CC1)[n]1nc(/C=C/c2ccccc2)cc1 ATYFLPYBMPJORO-RMKNXTFCSA-N 0.000 description 1
- GDXXARMBXKJSJR-VAWYXSNFSA-N O=C(c1ccccc1)[n]1nc(/C=C/c2ccccc2)cc1 Chemical compound O=C(c1ccccc1)[n]1nc(/C=C/c2ccccc2)cc1 GDXXARMBXKJSJR-VAWYXSNFSA-N 0.000 description 1
- NQRAOTITHAVKIQ-UXBLZVDNSA-N OOc(cc1)ccc1C(C1C=CC(/C=C/c2ccccc2)=NC1)=O Chemical compound OOc(cc1)ccc1C(C1C=CC(/C=C/c2ccccc2)=NC1)=O NQRAOTITHAVKIQ-UXBLZVDNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43553302P | 2002-12-21 | 2002-12-21 | |
| US60/435,533 | 2002-12-21 | ||
| US10/740,708 | 2003-12-18 | ||
| US10/740,708 US7192976B2 (en) | 2002-12-21 | 2003-12-18 | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| PCT/US2003/040917 WO2004058721A2 (en) | 2002-12-21 | 2003-12-19 | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1747730A CN1747730A (zh) | 2006-03-15 |
| CN1747730B true CN1747730B (zh) | 2013-05-29 |
Family
ID=32685400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2003801095507A Expired - Fee Related CN1747730B (zh) | 2002-12-21 | 2003-12-19 | 肝细胞生长因子(分散因子)活性的吡唑衍生物调节剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US7192976B2 (enExample) |
| EP (2) | EP1572199B1 (enExample) |
| JP (3) | JP5160019B2 (enExample) |
| CN (1) | CN1747730B (enExample) |
| AU (1) | AU2003301224C1 (enExample) |
| CA (1) | CA2511199C (enExample) |
| DK (2) | DK2292227T3 (enExample) |
| HU (1) | HUE030700T2 (enExample) |
| IL (1) | IL169316A (enExample) |
| WO (1) | WO2004058721A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192976B2 (en) | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US20110230407A1 (en) * | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
| US7879898B1 (en) | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP2313093A4 (en) * | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY |
| WO2010068287A2 (en) * | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2011006072A2 (en) * | 2009-07-10 | 2011-01-13 | Northwestern University | Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia |
| US20120190668A1 (en) * | 2009-08-12 | 2012-07-26 | Oehlen Lambertus J W M | Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| JP2014509297A (ja) * | 2010-10-05 | 2014-04-17 | アンジオン バイオメディカ コーポレイション | 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法 |
| JP6173298B2 (ja) * | 2011-04-02 | 2017-08-02 | ワシントン ステート ユニバーシティ | 治療薬としての肝細胞増殖因子模倣体 |
| WO2012151349A1 (en) | 2011-05-03 | 2012-11-08 | Liu Shu Q | Neuroprotection by hepatic cells and hepatocyte secretory factors |
| UY34200A (es) * | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| RU2678830C2 (ru) | 2013-03-15 | 2019-02-04 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
| KR20150130405A (ko) | 2013-03-15 | 2015-11-23 | 베르선 코포레이션 | 트롬빈의 억제제로서의 할로게노피라졸 |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| HK1246164A1 (zh) | 2015-02-27 | 2018-09-07 | Verseon Corporation | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| KR20220004083A (ko) | 2019-04-11 | 2022-01-11 | 앤지온 바이오메디카 코포레이션 | (e)-3-[2-(2-티에닐)비닐]-1h-피라졸의 고체 형태 |
| WO2021087392A1 (en) * | 2019-10-31 | 2021-05-06 | Angion Biomedica Corp. | Improving renal function after kidney transplantation |
| WO2021183774A1 (en) * | 2020-03-12 | 2021-09-16 | Angion Biomedica Corp. | Treating acute respiratory distress |
| EP4228626A2 (en) * | 2020-10-14 | 2023-08-23 | Angion Biomedica Corp. | Preparation of terevalefim and formulations thereof |
| CA3196582A1 (en) * | 2020-11-02 | 2022-05-05 | Leen Kawas | Bicyclic compounds and uses thereof for the treatment of diseases |
| WO2022217070A1 (en) * | 2021-04-09 | 2022-10-13 | Angion Biomedica Corp. | Hgf/sf mimetic compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE138770C (enExample) * | ||||
| JPS48713Y1 (enExample) | 1967-12-19 | 1973-01-09 | ||
| JPS48713U (enExample) | 1971-05-22 | 1973-01-08 | ||
| DD138770A1 (de) * | 1978-09-20 | 1979-11-21 | Juergen Liebscher | Verfahren zur herstellung von 5-styryl-pyrazolen und ihren vinylogen |
| JPH02193994A (ja) | 1989-01-23 | 1990-07-31 | Kyowa Hakko Kogyo Co Ltd | ピリダジノン誘導体 |
| FR2669633B1 (fr) * | 1990-11-23 | 1993-01-22 | Adir | Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5476076A (en) * | 1994-12-06 | 1995-12-19 | Zhou; Zhishan | Internal combustion piston engine utilizing interference movable fit technology |
| JPH11288112A (ja) | 1998-04-06 | 1999-10-19 | Mitsubishi Paper Mills Ltd | 電子写真感光体 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| WO2001034650A1 (en) * | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
| EP1355921A2 (en) | 2000-06-29 | 2003-10-29 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| US6610726B2 (en) | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
| WO2004009599A1 (en) | 2002-07-19 | 2004-01-29 | Targacept, Inc. | Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
-
2003
- 2003-12-18 US US10/740,708 patent/US7192976B2/en not_active Expired - Lifetime
- 2003-12-19 CN CN2003801095507A patent/CN1747730B/zh not_active Expired - Fee Related
- 2003-12-19 AU AU2003301224A patent/AU2003301224C1/en not_active Ceased
- 2003-12-19 EP EP03814306.1A patent/EP1572199B1/en not_active Expired - Lifetime
- 2003-12-19 JP JP2004563939A patent/JP5160019B2/ja not_active Expired - Fee Related
- 2003-12-19 DK DK10011181.4T patent/DK2292227T3/en active
- 2003-12-19 CA CA2511199A patent/CA2511199C/en not_active Expired - Lifetime
- 2003-12-19 DK DK03814306.1T patent/DK1572199T3/da active
- 2003-12-19 WO PCT/US2003/040917 patent/WO2004058721A2/en not_active Ceased
- 2003-12-19 EP EP10011181.4A patent/EP2292227B1/en not_active Expired - Lifetime
- 2003-12-19 HU HUE10011181A patent/HUE030700T2/en unknown
-
2004
- 2004-12-29 US US11/025,373 patent/US7265112B2/en not_active Expired - Lifetime
- 2004-12-29 US US11/024,615 patent/US7250437B2/en not_active Expired - Lifetime
-
2005
- 2005-06-21 IL IL169316A patent/IL169316A/en active IP Right Grant
-
2007
- 2007-08-13 US US11/891,618 patent/US8580834B2/en not_active Expired - Fee Related
-
2010
- 2010-08-23 JP JP2010186703A patent/JP5755417B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-07 US US14/047,907 patent/US9663471B2/en not_active Expired - Fee Related
-
2015
- 2015-01-30 JP JP2015016424A patent/JP2015078246A/ja active Pending
-
2019
- 2019-01-11 US US16/245,373 patent/US20190382348A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| ANAZALDI M ETAL.SYNTHESIS AND ANTIMICROBIAL ACTIVITY OFHETEROCYCLIC IONONELIKE DERIVATIVES.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY34 10.1999,34(10),837-842. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1747730B (zh) | 肝细胞生长因子(分散因子)活性的吡唑衍生物调节剂 | |
| US10899750B2 (en) | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| AU2003301224B2 (en) | Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity | |
| US20110237633A1 (en) | Small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| JP2014509297A (ja) | 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法 | |
| HK1085651B (en) | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130529 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |